Advanced search
Publication Cover
Renal Failure Volume 37, 2015 - Issue 9
Submit an article Journal homepage
1,255
Views
9
CrossRef citations to date
0
Altmetric
Brief Report

The effectiveness and safety of rituximab as induction therapy in ABO-compatible non-sensitized renal transplantation: a systematic review and meta-analysis of randomized controlled trials

Wisit CheungpasitpornDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA, Correspondence[email protected]
,
Charat ThongprayoonDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA,
,
Peter J. EdmondsSUNY Upstate Medical University, Syracuse, NY, USA,
,
Jackrapong BruminhentDepartment of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand, and
&
Kawin TangdhanakanondDepartment of Renal Medicine, Alexandra Hospital, Singapore, Singapore
Pages 1522-1526 | Received 14 Jun 2015, Accepted 24 Jul 2015, Published online: 31 Aug 2015

References

  • Bakr MA, Nagib AM, Donia AF. Induction immunosuppressive therapy in kidney transplantation. Exp Clin Transplant. 2014;12(Suppl. 1):60–69
  • Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC. Interleukin 2 receptor antagonists for renal transplant recipients: A meta-analysis of randomized trials. Transplantation. 2004;77:166–176
  • Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: A summary. Kidney Int. 2009;77:299–311
  • Matas AJ, Smith JM, Skeans MA, et al. Optn/srtr 2012 annual data report: Kidney. Am J Transplant. 2014;14(Suppl. 1):11–44
  • Ramanath V, Nistala R, Chaudhary K. Update on the role of rituximab in kidney diseases and transplant. Expert Opin Biol Ther. 2012;12:223–233
  • Barnett AN, Hadjianastassiou VG, Mamode N. Rituximab in renal transplantation. Transpl Int. 2013;26:563–575
  • Macklin PS, Morris PJ, Knight SR. A systematic review of the use of rituximab for desensitization in renal transplantation. Transplantation. 2014;98:794–805
  • Stroopinsky D, Katz T, Rowe JM, Melamed D, Avivi I. Rituximab-induced direct inhibition of t-cell activation. Cancer Immunol Immunother. 2012;61:1233–1241
  • van den Hoogen MW, Kamburova EG, Baas MC, et al. Rituximab as induction therapy after renal transplantation: A randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Transplant. 2015;15:407–416
  • Tyden G, Genberg H, Tollemar J, et al. A randomized, doubleblind, placebo-controlled, study of single-dose rituximab as induction in renal transplantation. Transplantation. 2009;87:1325–1329
  • Clatworthy MR, Watson CJ, Plotnek G, et al. B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med. 2009;360:2683–2685
  • Tsai MK, Lee CY, Yang CY, Yeh CC, Hu RH, Lee PH. Rituximab induction therapy provided additional immunosuppressive effect and functional benefit to non-sensitized renal transplant recipients. Am J Transplant. 2012;12:319
  • Macklin PS, Morris PJ, Knight SR. A systematic review of the use of rituximab as induction therapy in renal transplantation. Transplant Rev (Orlando). 2015;29:103–108
  • Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials. 1996;17:1–12
  • DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188
  • Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560
  • Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867–872
  • Tyden G, Ekberg H, Tufveson G, Mjornstedt L. A randomized, double-blind, placebo-controlled study of single dose rituximab as induction in renal transplantation: A 3-year follow-up. Transplantation. 2012;94:e21–e22
  • Genberg H, Hansson A, Wernerson A, Wennberg L, Tyden G. Pharmacodynamics of rituximab in kidney allotransplantation. Am J Transplant. 2006;6:2418–2428
  • Kyaw T, Tay C, Krishnamurthi S, et al. B1a b lymphocytes are atheroprotective by secreting natural igm that increases igm deposits and reduces necrotic cores in atherosclerotic lesions. Circ Res. 2011;109:830–840

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.